JP2015524804A - 局所消毒用製剤およびその使用 - Google Patents
局所消毒用製剤およびその使用 Download PDFInfo
- Publication number
- JP2015524804A JP2015524804A JP2015524357A JP2015524357A JP2015524804A JP 2015524804 A JP2015524804 A JP 2015524804A JP 2015524357 A JP2015524357 A JP 2015524357A JP 2015524357 A JP2015524357 A JP 2015524357A JP 2015524804 A JP2015524804 A JP 2015524804A
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- weight
- amount ranging
- topical
- microorganisms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 18
- 230000000699 topical effect Effects 0.000 title claims description 6
- 239000000645 desinfectant Substances 0.000 title description 64
- 239000000203 mixture Substances 0.000 claims abstract description 673
- 238000009472 formulation Methods 0.000 claims abstract description 669
- 244000005700 microbiome Species 0.000 claims abstract description 197
- 238000000034 method Methods 0.000 claims abstract description 155
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 138
- 230000002459 sustained effect Effects 0.000 claims abstract description 65
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 175
- 235000019441 ethanol Nutrition 0.000 claims description 102
- 239000000344 soap Substances 0.000 claims description 96
- 230000009467 reduction Effects 0.000 claims description 92
- 241000894006 Bacteria Species 0.000 claims description 89
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 89
- 230000000813 microbial effect Effects 0.000 claims description 80
- 238000012360 testing method Methods 0.000 claims description 67
- 150000003505 terpenes Chemical class 0.000 claims description 65
- 239000006210 lotion Substances 0.000 claims description 63
- 235000007586 terpenes Nutrition 0.000 claims description 58
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 53
- 229920001090 Polyaminopropyl biguanide Polymers 0.000 claims description 52
- 229960001950 benzethonium chloride Drugs 0.000 claims description 50
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 49
- 229940093424 polyaminopropyl biguanide Drugs 0.000 claims description 48
- 241000700605 Viruses Species 0.000 claims description 42
- 150000003751 zinc Chemical class 0.000 claims description 37
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 36
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 36
- 230000002147 killing effect Effects 0.000 claims description 36
- 238000005187 foaming Methods 0.000 claims description 35
- 208000015181 infectious disease Diseases 0.000 claims description 35
- 239000003599 detergent Substances 0.000 claims description 28
- 229920013819 hydroxyethyl ethylcellulose Polymers 0.000 claims description 23
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 22
- 229940042585 tocopherol acetate Drugs 0.000 claims description 22
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 21
- 239000000341 volatile oil Substances 0.000 claims description 21
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims description 19
- 241000233866 Fungi Species 0.000 claims description 18
- 239000004599 antimicrobial Substances 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 17
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 claims description 16
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 16
- 239000010642 eucalyptus oil Substances 0.000 claims description 16
- 229940044949 eucalyptus oil Drugs 0.000 claims description 16
- 229930002886 farnesol Natural products 0.000 claims description 16
- 229940043259 farnesol Drugs 0.000 claims description 16
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 claims description 16
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims description 15
- 241000192125 Firmicutes Species 0.000 claims description 14
- 239000003974 emollient agent Substances 0.000 claims description 14
- 229940101267 panthenol Drugs 0.000 claims description 14
- 235000020957 pantothenol Nutrition 0.000 claims description 14
- 239000011619 pantothenol Substances 0.000 claims description 14
- -1 scrubs Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 239000000499 gel Substances 0.000 claims description 13
- 229930004725 sesquiterpene Natural products 0.000 claims description 13
- 229940123208 Biguanide Drugs 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 12
- 230000009977 dual effect Effects 0.000 claims description 12
- 150000004354 sesquiterpene derivatives Chemical class 0.000 claims description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 11
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 10
- 206010040880 Skin irritation Diseases 0.000 claims description 10
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 10
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 10
- 230000036556 skin irritation Effects 0.000 claims description 10
- 231100000475 skin irritation Toxicity 0.000 claims description 10
- 229960003500 triclosan Drugs 0.000 claims description 10
- 239000011670 zinc gluconate Substances 0.000 claims description 10
- 235000011478 zinc gluconate Nutrition 0.000 claims description 10
- 229960000306 zinc gluconate Drugs 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 9
- 230000002085 persistent effect Effects 0.000 claims description 9
- 229910052700 potassium Inorganic materials 0.000 claims description 9
- 235000019155 vitamin A Nutrition 0.000 claims description 9
- 239000011719 vitamin A Substances 0.000 claims description 9
- 235000019156 vitamin B Nutrition 0.000 claims description 9
- 239000011720 vitamin B Substances 0.000 claims description 9
- 235000019154 vitamin C Nutrition 0.000 claims description 9
- 239000011718 vitamin C Substances 0.000 claims description 9
- 235000019168 vitamin K Nutrition 0.000 claims description 9
- 239000011712 vitamin K Substances 0.000 claims description 9
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 8
- 239000011576 zinc lactate Substances 0.000 claims description 8
- 235000000193 zinc lactate Nutrition 0.000 claims description 8
- 229940050168 zinc lactate Drugs 0.000 claims description 8
- 229940008099 dimethicone Drugs 0.000 claims description 7
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 7
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 7
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 7
- 230000001052 transient effect Effects 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 230000002458 infectious effect Effects 0.000 claims description 4
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000011012 sanitization Methods 0.000 claims description 4
- 239000002453 shampoo Substances 0.000 claims description 4
- 238000004381 surface treatment Methods 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 238000010348 incorporation Methods 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 106
- 210000003491 skin Anatomy 0.000 description 83
- 230000000694 effects Effects 0.000 description 47
- 230000000249 desinfective effect Effects 0.000 description 36
- 210000003811 finger Anatomy 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 238000011109 contamination Methods 0.000 description 30
- 229910001868 water Inorganic materials 0.000 description 30
- 230000002829 reductive effect Effects 0.000 description 29
- 210000004247 hand Anatomy 0.000 description 26
- 201000010099 disease Diseases 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 241000588724 Escherichia coli Species 0.000 description 24
- 238000005406 washing Methods 0.000 description 23
- 230000006870 function Effects 0.000 description 21
- 241000607715 Serratia marcescens Species 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 20
- 230000005540 biological transmission Effects 0.000 description 19
- 230000007774 longterm Effects 0.000 description 19
- 238000004659 sterilization and disinfection Methods 0.000 description 18
- 230000000844 anti-bacterial effect Effects 0.000 description 17
- 239000000725 suspension Substances 0.000 description 16
- 230000034994 death Effects 0.000 description 15
- 231100000517 death Toxicity 0.000 description 15
- 239000003906 humectant Substances 0.000 description 15
- 230000007423 decrease Effects 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 210000001015 abdomen Anatomy 0.000 description 13
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 13
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000011701 zinc Substances 0.000 description 12
- 229910052725 zinc Inorganic materials 0.000 description 12
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 11
- 229960003260 chlorhexidine Drugs 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 238000005070 sampling Methods 0.000 description 11
- 230000008901 benefit Effects 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 229920002678 cellulose Polymers 0.000 description 9
- 239000001913 cellulose Substances 0.000 description 9
- 235000010980 cellulose Nutrition 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 229940088594 vitamin Drugs 0.000 description 9
- 229930003231 vitamin Natural products 0.000 description 9
- 235000013343 vitamin Nutrition 0.000 description 9
- 239000011782 vitamin Substances 0.000 description 9
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 8
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 8
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 8
- 208000002874 Acne Vulgaris Diseases 0.000 description 7
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 7
- 241001263478 Norovirus Species 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 206010000496 acne Diseases 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 7
- 229960005150 glycerol Drugs 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000002688 persistence Effects 0.000 description 7
- 210000003813 thumb Anatomy 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 210000000707 wrist Anatomy 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 239000002304 perfume Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Chemical compound CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 4
- 244000144927 Aloe barbadensis Species 0.000 description 4
- 235000002961 Aloe barbadensis Nutrition 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 102000029797 Prion Human genes 0.000 description 4
- 108091000054 Prion Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000003139 biocide Substances 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229940048866 lauramine oxide Drugs 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 230000000474 nursing effect Effects 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000008399 tap water Substances 0.000 description 4
- 235000020679 tap water Nutrition 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000228245 Aspergillus niger Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 241000207199 Citrus Species 0.000 description 3
- 206010011409 Cross infection Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000011399 aloe vera Nutrition 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 235000020971 citrus fruits Nutrition 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 3
- 210000004905 finger nail Anatomy 0.000 description 3
- 210000004904 fingernail bed Anatomy 0.000 description 3
- 229940098803 hibiclens Drugs 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000000282 nail Anatomy 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 244000309711 non-enveloped viruses Species 0.000 description 3
- 231100000344 non-irritating Toxicity 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000010079 rubber tapping Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000005201 scrubbing Methods 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007655 standard test method Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 239000000516 sunscreening agent Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JSNRRGGBADWTMC-UHFFFAOYSA-N (6E)-7,11-dimethyl-3-methylene-1,6,10-dodecatriene Chemical compound CC(C)=CCCC(C)=CCCC(=C)C=C JSNRRGGBADWTMC-UHFFFAOYSA-N 0.000 description 2
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 description 2
- RNFJDJUURJAICM-UHFFFAOYSA-N 2,2,4,4,6,6-hexaphenoxy-1,3,5-triaza-2$l^{5},4$l^{5},6$l^{5}-triphosphacyclohexa-1,3,5-triene Chemical compound N=1P(OC=2C=CC=CC=2)(OC=2C=CC=CC=2)=NP(OC=2C=CC=CC=2)(OC=2C=CC=CC=2)=NP=1(OC=1C=CC=CC=1)OC1=CC=CC=C1 RNFJDJUURJAICM-UHFFFAOYSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- KUXUALPOSMRJSW-IFWQJVLJSA-N 2-[6-[[amino-[[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 KUXUALPOSMRJSW-IFWQJVLJSA-N 0.000 description 2
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 2
- 241000589875 Campylobacter jejuni Species 0.000 description 2
- 241000709687 Coxsackievirus Species 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000714201 Feline calicivirus Species 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 206010017918 Gastroenteritis viral Diseases 0.000 description 2
- 239000005792 Geraniol Substances 0.000 description 2
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 239000001140 aloe barbadensis leaf extract Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000002882 anti-plaque Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 229960002788 cetrimonium chloride Drugs 0.000 description 2
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 2
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 239000011928 denatured alcohol Substances 0.000 description 2
- 239000002781 deodorant agent Substances 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- ILRSCQWREDREME-UHFFFAOYSA-N dodecanamide Chemical compound CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000003063 flame retardant Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 229940113087 geraniol Drugs 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000008233 hard water Substances 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000937 inactivator Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940001447 lactate Drugs 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229930003658 monoterpene Natural products 0.000 description 2
- 150000002773 monoterpene derivatives Chemical class 0.000 description 2
- 235000002577 monoterpenes Nutrition 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000009340 pathogen transmission Effects 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000036620 skin dryness Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- YHTCXUSSQJMLQD-GIXZANJISA-N (2E,6E,10E,14E)-geranylfarnesol Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CO YHTCXUSSQJMLQD-GIXZANJISA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- SNPLKNRPJHDVJA-SSDOTTSWSA-N (2s)-2,4-dihydroxy-n-(3-hydroxypropyl)-3,3-dimethylbutanamide Chemical compound OCC(C)(C)[C@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-SSDOTTSWSA-N 0.000 description 1
- CXENHBSYCFFKJS-UHFFFAOYSA-N (3E,6E)-3,7,11-Trimethyl-1,3,6,10-dodecatetraene Natural products CC(C)=CCCC(C)=CCC=C(C)C=C CXENHBSYCFFKJS-UHFFFAOYSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- RPZANUYHRMRTTE-UHFFFAOYSA-N 2,3,4-trimethoxy-6-(methoxymethyl)-5-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[3,4,5-tris(2-hydroxybutoxy)-6-[4,5,6-tris(2-hydroxybutoxy)-2-(2-hydroxybutoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]butan-2-ol Chemical compound COC1C(OC)C(OC)C(COC)OC1OC1C(OC)C(OC)C(OC)OC1COC.CCC(O)COC1C(OCC(O)CC)C(OCC(O)CC)C(COCC(O)CC)OC1OC1C(OCC(O)CC)C(OCC(O)CC)C(OCC(O)CC)OC1COCC(O)CC RPZANUYHRMRTTE-UHFFFAOYSA-N 0.000 description 1
- HMKKIXGYKWDQSV-SDNWHVSQSA-N 2-Pentyl-3-phenyl-2-propenal Chemical compound CCCCC\C(C=O)=C/C1=CC=CC=C1 HMKKIXGYKWDQSV-SDNWHVSQSA-N 0.000 description 1
- 229930008411 3,7-dimethylocta-2,6-dien-1-ol Natural products 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- XZEUYTKSAYNYPK-UHFFFAOYSA-N 3beta-29-Norcycloart-24-en-3-ol Natural products C1CC2(C)C(C(CCC=C(C)C)C)CCC2(C)C2CCC3C(C)C(O)CCC33C21C3 XZEUYTKSAYNYPK-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000007436 Cananga odorata Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- RRTBTJPVUGMUNR-UHFFFAOYSA-N Cycloartanol Natural products C12CCC(C(C(O)CC3)(C)C)C3C2(CC)CCC2(C)C1(C)CCC2C(C)CCCC(C)C RRTBTJPVUGMUNR-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- RUPBZQFQVRMKDG-UHFFFAOYSA-M Didecyldimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC RUPBZQFQVRMKDG-UHFFFAOYSA-M 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- 241000714214 Feline calicivirus strain F9 Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- HVXLSFNCWWWDPA-UHFFFAOYSA-N Isocycloartenol Natural products C1CC(O)C(C)(C)C2C31CC13CCC3(C)C(C(CCCC(C)=C)C)CCC3(C)C1CC2 HVXLSFNCWWWDPA-UHFFFAOYSA-N 0.000 description 1
- BJIOGJUNALELMI-ONEGZZNKSA-N Isoeugenol Natural products COC1=CC(\C=C\C)=CC=C1O BJIOGJUNALELMI-ONEGZZNKSA-N 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- HXQRIQXPGMPSRW-UHZRDUGNSA-N Pollinastanol Natural products O[C@@H]1C[C@H]2[C@@]3([C@]4([C@H]([C@@]5(C)[C@@](C)([C@H]([C@H](CCCC(C)C)C)CC5)CC4)CC2)C3)CC1 HXQRIQXPGMPSRW-UHZRDUGNSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000201788 Staphylococcus aureus subsp. aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FRJSECSOXKQMOD-HQRMLTQVSA-N Taxa-4(5),11(12)-diene Chemical compound C1C[C@]2(C)CCC=C(C)[C@H]2C[C@@H]2CCC(C)=C1C2(C)C FRJSECSOXKQMOD-HQRMLTQVSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- YHTCXUSSQJMLQD-UHFFFAOYSA-N all-E-geranylfarnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCO YHTCXUSSQJMLQD-UHFFFAOYSA-N 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- OXQKEKGBFMQTML-UHFFFAOYSA-N alpha-Glucoheptitol Chemical compound OCC(O)C(O)C(O)C(O)C(O)CO OXQKEKGBFMQTML-UHFFFAOYSA-N 0.000 description 1
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000002272 anti-calculus Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229940049746 avagard Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001342 boswellia carteri birdw. oil Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N butane-1,2,3,4-tetrol Chemical compound OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229960000228 cetalkonium chloride Drugs 0.000 description 1
- SXPWTBGAZSPLHA-UHFFFAOYSA-M cetalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SXPWTBGAZSPLHA-UHFFFAOYSA-M 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 229960003431 cetrimonium Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- WDRFFJWBUDTUCA-UHFFFAOYSA-N chlorhexidine acetate Chemical compound CC(O)=O.CC(O)=O.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WDRFFJWBUDTUCA-UHFFFAOYSA-N 0.000 description 1
- 229960001884 chlorhexidine diacetate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- BJIOGJUNALELMI-ARJAWSKDSA-N cis-isoeugenol Chemical compound COC1=CC(\C=C/C)=CC=C1O BJIOGJUNALELMI-ARJAWSKDSA-N 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 239000001524 citrus aurantium oil Substances 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- ONQRKEUAIJMULO-YBXTVTTCSA-N cycloartenol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@@H](CCC=C(C)C)C)CC[C@@]3(C)[C@@H]1CC2 ONQRKEUAIJMULO-YBXTVTTCSA-N 0.000 description 1
- YNBJLDSWFGUFRT-UHFFFAOYSA-N cycloartenol Natural products CC(CCC=C(C)C)C1CCC2(C)C1(C)CCC34CC35CCC(O)C(C)(C)C5CCC24C YNBJLDSWFGUFRT-UHFFFAOYSA-N 0.000 description 1
- FODTZLFLDFKIQH-UHFFFAOYSA-N cycloartenol trans-ferulate Natural products C1=C(O)C(OC)=CC(C=CC(=O)OC2C(C3CCC4C5(C)CCC(C5(C)CCC54CC53CC2)C(C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-UHFFFAOYSA-N 0.000 description 1
- 239000001941 cymbopogon citratus dc and cymbopogon flexuosus oil Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N d-arabitol Chemical compound OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229960004670 didecyldimethylammonium chloride Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 1
- CVOQYKPWIVSMDC-UHFFFAOYSA-L dipotassium;butanedioate Chemical compound [K+].[K+].[O-]C(=O)CCC([O-])=O CVOQYKPWIVSMDC-UHFFFAOYSA-L 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 229940079868 disodium laureth sulfosuccinate Drugs 0.000 description 1
- YGAXLGGEEQLLKV-UHFFFAOYSA-L disodium;4-dodecoxy-4-oxo-2-sulfonatobutanoate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOC(=O)CC(C([O-])=O)S([O-])(=O)=O YGAXLGGEEQLLKV-UHFFFAOYSA-L 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- MFGZXPGKKJMZIY-UHFFFAOYSA-N ethyl 5-amino-1-(4-sulfamoylphenyl)pyrazole-4-carboxylate Chemical compound NC1=C(C(=O)OCC)C=NN1C1=CC=C(S(N)(=O)=O)C=C1 MFGZXPGKKJMZIY-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229930009668 farnesene Natural products 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000004872 foam stabilizing agent Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- WPFVBOQKRVRMJB-UHFFFAOYSA-N hydroxycitronellal Chemical compound O=CCC(C)CCCC(C)(C)O WPFVBOQKRVRMJB-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 229940116335 lauramide Drugs 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960002285 methylbenzethonium chloride Drugs 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- UTBABEVADWVTHM-UHFFFAOYSA-N n,n-dimethylpropan-1-amine;octadecanamide Chemical compound CCCN(C)C.CCCCCCCCCCCCCCCCCC(N)=O UTBABEVADWVTHM-UHFFFAOYSA-N 0.000 description 1
- 229940049292 n-(3-(dimethylamino)propyl)octadecanamide Drugs 0.000 description 1
- WWVIUVHFPSALDO-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCN(C)C WWVIUVHFPSALDO-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- HLERILKGMXJNBU-UHFFFAOYSA-N norvaline betaine Chemical compound CCCC(C([O-])=O)[N+](C)(C)C HLERILKGMXJNBU-UHFFFAOYSA-N 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001298 pelargonium graveolens oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 150000003097 polyterpenes Chemical class 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- ASUAYTHWZCLXAN-UHFFFAOYSA-N prenol Chemical compound CC(C)=CCO ASUAYTHWZCLXAN-UHFFFAOYSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012913 prioritisation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000010671 sandalwood oil Substances 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229930002368 sesterterpene Natural products 0.000 description 1
- 150000002653 sesterterpene derivatives Chemical class 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000037370 skin discoloration Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940116411 terpineol Drugs 0.000 description 1
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 1
- 150000003535 tetraterpenes Chemical class 0.000 description 1
- 235000009657 tetraterpenes Nutrition 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- BJIOGJUNALELMI-UHFFFAOYSA-N trans-isoeugenol Natural products COC1=CC(C=CC)=CC=C1O BJIOGJUNALELMI-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- BIKXLKXABVUSMH-UHFFFAOYSA-N trizinc;diborate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]B([O-])[O-].[O-]B([O-])[O-] BIKXLKXABVUSMH-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- GAAKLDANOSASAM-UHFFFAOYSA-N undec-10-enoic acid;zinc Chemical compound [Zn].OC(=O)CCCCCCCCC=C GAAKLDANOSASAM-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- SRWMQSFFRFWREA-UHFFFAOYSA-M zinc formate Chemical compound [Zn+2].[O-]C=O SRWMQSFFRFWREA-UHFFFAOYSA-M 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 description 1
- 229910000165 zinc phosphate Inorganic materials 0.000 description 1
- 229940032991 zinc picolinate Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940118257 zinc undecylenate Drugs 0.000 description 1
- VRGNUPCISFMPEM-ZVGUSBNCSA-L zinc;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Zn+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VRGNUPCISFMPEM-ZVGUSBNCSA-L 0.000 description 1
- JNPQFTCBVDSMDO-UHFFFAOYSA-L zinc;2,3-dihydroxypropanoate Chemical compound [Zn+2].OCC(O)C([O-])=O.OCC(O)C([O-])=O JNPQFTCBVDSMDO-UHFFFAOYSA-L 0.000 description 1
- MCOGTQGPHPAUJN-UHFFFAOYSA-L zinc;2-hydroxyacetate Chemical compound [Zn+2].OCC([O-])=O.OCC([O-])=O MCOGTQGPHPAUJN-UHFFFAOYSA-L 0.000 description 1
- WDHVIZKSFZNHJB-UHFFFAOYSA-L zinc;butanoate Chemical compound [Zn+2].CCCC([O-])=O.CCCC([O-])=O WDHVIZKSFZNHJB-UHFFFAOYSA-L 0.000 description 1
- XDWXRAYGALQIFG-UHFFFAOYSA-L zinc;propanoate Chemical compound [Zn+2].CCC([O-])=O.CCC([O-])=O XDWXRAYGALQIFG-UHFFFAOYSA-L 0.000 description 1
- NHVUUBRKFZWXRN-UHFFFAOYSA-L zinc;pyridine-2-carboxylate Chemical compound C=1C=CC=NC=1C(=O)O[Zn]OC(=O)C1=CC=CC=N1 NHVUUBRKFZWXRN-UHFFFAOYSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/43—Guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
Description
感染および微生物
抗微生物効果
抗微生物製剤
補助的な有益効果
(実施例1−持続型および非持続型石鹸の試験)
(実施例2−改変持続型および非持続型石鹸製剤の試験)
(実施例3−ローション製剤の抗微生物試験)
(実施例4−E.コリ(E.Coli)に対する清浄剤製剤の抗微生物試験)
(実施例5−消毒用製剤は広域スペクトルおよび急速な抗微生物効果を示す)
方法
結果
(実施例6−インビボでの医療従事者洗浄試験における消毒用製剤の効能)
方法
(実施例7−成人手指に対する消毒用製剤の細菌除去効能)
(実施例8−消毒用製剤の抗微生物的効能延長)
(実施例9−起泡性石鹸と標準的な石鹸の、長時間抗微生物的効能の比較)
(実施例10−薬剤耐性細菌に対する石鹸製剤の効能の比較)
(実施例11−薬剤耐性細菌に対するリーブオン消毒製剤の効能の比較)
(実施例12−ノロウイルスに対する消毒製剤の効能の比較)
インプット対照
ベースライン対照
試験材料の効能
結果
Claims (121)
- 二重作用即時型および持続型微生物減少の方法であって、
複数の微生物により汚染された表面に局所製剤を適用することを含み、
前記局所製剤が、テルペンと、酢酸トコフェロールと、ポリアミノプロピルビグアナイドと、塩化ベンゼトニウムおよび塩化ベンザルコニウムからなる群から選択される少なくとも1つの第四級アンモニウム塩と、を含み;
前記製剤が、前記複数の微生物の少なくとも99%を該微生物との接触の20秒以内に死滅させ;
前記製剤が、前記製剤適用の少なくとも4時間後に、前記複数の微生物の少なくとも90%を死滅させるように作製されており;
前記複数の微生物が次のうち2以上:グラム陽性細菌、グラム陰性細菌、真菌、酵母およびウイルス、を含む、
方法。 - 前記局所製剤がトリクロサン不含である、請求項1に記載の方法。
- 前記局所製剤がアルコール不含である、請求項1に記載の方法。
- 前記局所製剤がトリクロサンおよびアルコールの両方不含である、請求項1に記載の方法。
- 前記微生物が、グラム陽性およびグラム陰性細菌を含む、請求項3に記載の方法。
- 前記局所製剤が非ジェル清浄剤であり、
前記テルペンが前記製剤の約0.1重量%から約2重量%の範囲の量で存在し、
前記酢酸トコフェロールが前記製剤の約0.01重量%から約1.0重量%の範囲の量で存在し、
前記ポリアミノプロピルビグアナイドが前記製剤の約0.05重量%から約3重量%の範囲の量で存在し、
前記少なくとも1つの第四級アンモニウム塩が、前記製剤の約0.1重量%から約1.5重量%の範囲の量で存在し、
前記製剤が、該製剤の約1.5重量%から約3.5重量%の範囲の量のグリセリンをさらに含み、
前記製剤が、該製剤の約0.5重量%から約2.0重量%の範囲の量のジメチコンをさらに含み、
前記製剤が、該製剤の約0.1重量%から約2重量%の範囲の量のパンテノールをさらに含み、
前記製剤が、該製剤の約0.4重量%から約1.0重量%の範囲の量のヒドロキシエチルエチルセルロースをさらに含む、
請求項1に記載の方法。 - 前記局所製剤が消毒用ローションであり、
前記テルペンが前記製剤の約0.1重量%から約2重量%の範囲の量で存在し、
前記酢酸トコフェロールが前記製剤の約0.01重量%から約1.0重量%の範囲の量で存在し、
前記ポリアミノプロピルビグアナイドが前記製剤の約0.05重量%から約3重量%の範囲の量で存在し、
前記少なくとも1つの第四級アンモニウム塩が、前記製剤の約0.1重量%から約1.5重量%の範囲の量で存在し、
前記製剤が、該製剤の約1.5重量%から約3.5重量%の範囲の量のグリセリンをさらに含み、
前記製剤が、該製剤の約0.5重量%から約2.0重量%の範囲の量のジメチコンをさらに含み、
前記製剤が、該製剤の約0.1重量%から約2重量%の範囲の量のパンテノールをさらに含み、
前記製剤が、該製剤の約0.4重量%から約1.0重量%の範囲の量のヒドロキシエチルエチルセルロースをさらに含み、
前記製剤が、該製剤の約0.1重量%から約2重量%の範囲の量の1以上の亜鉛塩をさらに含み、
前記製剤が、該製剤の約0.1重量%から約1.0重量%の範囲の量のジグルコン酸クロルヘキシジンをさらに含む、
請求項1に記載の方法。 - 前記テルペンが、前記局所製剤中に該製剤の約0.25重量%から約0.60重量%の範囲の量で存在する、請求項1に記載の方法。
- 前記酢酸トコフェロールが、前記局所製剤中に該製剤の約0.05重量%から約0.5重量%の範囲の量で存在する、請求項1に記載の方法。
- 前記ポリアミノプロピルビグアナイドが、前記製剤の約0.05重量%から約0.20重量%の範囲の量で存在する、請求項1に記載の方法。
- 前記少なくとも1つの第四級アンモニウム塩が、前記製剤の約0.01重量%から約0.40重量%の範囲の量で存在する、請求項1に記載の方法。
- 前記第四級アンモニウム塩が、塩化ベンゼトニウムを含む、請求項11に記載の方法。
- 前記テルペンがセスキテルペンを含む、請求項1に記載の方法。
- 前記セスキテルペンがファルネソールを含む、請求項13に記載の方法。
- 前記局所製剤の適用が、約0.1から0.8mLの前記製剤を前記表面に施与することを含む、請求項1に記載の方法。
- 前記製剤適用後4時間での該製剤の効能が、前記表面への該製剤の再適用がなくとも達成される、請求項1に記載の方法。
- 前記表面がヒト皮膚である、請求項1に記載の方法。
- 前記適用が皮膚刺激作用を誘導しない、請求項17に記載の方法。
- 前記表面が動物皮膚である、請求項1に記載の方法。
- 前記適用が皮膚刺激作用を誘導しない、請求項19に記載の方法。
- 前記表面が無機表面である、請求項1に記載の方法。
- 前記局所製剤が、該製剤の約8重量%から約20重量%の範囲の量のアルコールをさらに含む、請求項1から21の何れか1項に記載の方法。
- 前記局所製剤が、該製剤の約0.10重量%から約0.40重量%の範囲の量のグルコン酸クロルヘキシジンをさらに含む、請求項1から6または8から21の何れか1項に記載の方法。
- 前記局所製剤が、該製剤の約0.05重量%から約0.20重量%の範囲の量のヒドロキシエチルエチルセルロースをさらに含む、請求項1から5または8から21の何れか1項に記載の方法。
- 前記局所製剤が、該製剤の約0.05重量%から約0.60重量%の範囲の量の1以上の亜鉛塩をさらに含む、請求項1から6または8から21の何れか1項に記載の方法。
- 前記1以上の亜鉛塩が乳酸亜鉛を含む、請求項25に記載の方法。
- 前記1以上の亜鉛塩がグルコン酸亜鉛を含む、請求項25に記載の方法。
- 前記局所製剤が、該製剤の約0.25重量%から約0.60重量%の範囲の量のパンテノールをさらに含む、請求項1から5または8から21の何れか1項に記載の方法。
- 前記局所製剤が、1以上のさらなる皮膚軟化薬化合物をさらに含む、請求項1から21の何れか1項に記載の方法。
- 前記局所製剤が、ビタミンA、B、KおよびCのうちの1以上をさらに含む、請求項1から21の何れか1項に記載の方法。
- 前記局所製剤が精油をさらに含む、請求項1から21の何れか1項に記載の方法。
- 前記精油がユーカリ油を含む、請求項31に記載の方法。
- 前記ユーカリ油が、前記製剤の約0.05重量%から約0.5重量%の範囲の量で存在する、請求項32に記載の方法。
- 二重作用即時型および持続型微生物減少の方法であって、
グラム陽性およびグラム陰性細菌の両方により汚染された表面に局所製剤を適用することを含み、
前記局所製剤が、テルペンと、ポリアミノプロピルビグアナイドと、塩化ベンゼトニウムおよび塩化ベンザルコニウムからなる群から選択される少なくとも1つの第四級アンモニウム塩と、を含み;
前記製剤が、複数の微生物の少なくとも99%を前記微生物との接触の20秒以内に死滅させ;
前記製剤が、前記製剤適用の少なくとも4時間後に、グラム陽性およびグラム陰性細菌の両方の少なくとも90%を死滅させるように作製されている、
方法。 - 二重作用即時型および持続型微生物減少の方法であって、
複数の微生物により汚染された表面に局所製剤を適用することを含み、
前記局所製剤が、テルペンと、ポリアミノプロピルビグアナイドと、塩化ベンゼトニウムおよび塩化ベンザルコニウムからなる群から選択される少なくとも1つの第四級アンモニウム塩と、を含み;
前記製剤が、前記複数の微生物の少なくとも99%を該微生物との接触の20秒以内に死滅させ;
前記製剤が、前記製剤適用の少なくとも4時間後に、該複数の微生物の少なくとも90%を死滅させるように作製されており;
前記複数の微生物が次のうち2以上:グラム陽性細菌、グラム陰性細菌、真菌およびウイルス、を含む、
方法。 - 前記局所製剤が石鹸であり、
前記テルペンが前記製剤の約0.1重量%から約1.0重量%の範囲の量で存在し、
前記ポリアミノプロピルビグアナイドが前記製剤の約0.01重量%から約0.5重量%の範囲の量で存在し、
前記少なくとも1つの第四級アンモニウム塩が、前記製剤の約0.05重量%から約2.0重量%の範囲の量で存在し、
前記製剤が、該製剤の約0.1重量%から約2.0重量%の範囲の量の亜鉛塩をさらに含み、
前記製剤が、該製剤の約5.0重量%から約20.0重量%の範囲の量のエチルアルコールをさらに含む、
請求項34または35に記載の方法。 - 前記局所製剤が、前記製剤の約60重量%から約90重量%の範囲の量のアルコールをさらに含む、請求項34または35に記載の方法。
- 前記表面がヒトもしくは動物の皮膚または無機表面である、請求項34から37の何れか1項に記載の方法。
- 前記表面がヒトまたは動物の皮膚であり、前記適用が皮膚刺激作用を誘導しない、請求項38に記載の方法。
- 前記局所製剤が約5から約30秒以内に乾燥する、請求項34から39の何れか1項に記載の方法。
- 前記細菌が一過性細菌を含む、請求項34から40の何れか1項に記載の方法。
- 前記テルペンが、前記局所製剤中に該製剤の約0.25重量%から約0.60重量%の範囲の量で存在する、請求項34から41の何れか1項に記載の方法。
- 前記ポリアミノプロピルビグアナイドが、前記製剤の約0.05重量%から約0.20重量%の範囲の量で存在する、請求項34から42の何れか1項に記載の方法。
- 前記少なくとも1つの第四級アンモニウム塩が、前記製剤の約0.10重量%から約0.40重量%の範囲の量で存在する、請求項34から43の何れか1項に記載の方法。
- 前記第四級アンモニウム塩が塩化ベンゼトニウムを含む、請求項44に記載の方法。
- 前記局所製剤が、前記製剤の約0.05重量%から約0.20重量%の範囲の量のヒドロキシエチルエチルセルロースをさらに含む、請求項34から45の何れか1項に記載の方法。
- 前記テルペンがセスキテルペンを含む、請求項34から46の何れか1項に記載の方法。
- 前記セスキテルペンがファルネソールを含む、請求項47に記載の方法。
- 前記局所製剤が、前記製剤の約0.25重量%から約0.60重量%の範囲の量のパンテノールをさらに含む、請求項34から48の何れか1項に記載の方法。
- 前記局所製剤が、1以上のさらなる皮膚軟化薬化合物をさらに含む、請求項34から49の何れか1項に記載の方法。
- 前記局所製剤が、ビタミンA、B、E、KおよびCのうちの1以上をさらに含む、請求項34から50の何れか1項に記載の方法。
- 前記局所製剤の適用が、約0.1から0.8mLの前記製剤を前記表面に施与することを含む、請求項34から51の何れか1項に記載の方法。
- 前記製剤適用後4時間での前記製剤の効能が、前記表面への前記製剤の再適用がなくとも達成される、請求項34から52の何れか1項に記載の方法。
- 即時型微生物減少の方法であって、
グラム陽性およびグラム陰性細菌の両方により汚染された表面に局所製剤を適用することを含み、
前記局所製剤が、テルペンと、酢酸トコフェロールと、ポリアミノプロピルビグアナイドと、塩化ベンゼトニウムおよび塩化ベンザルコニウムからなる群から選択される少なくとも1つの第四級アンモニウム塩と、を含み、
前記製剤が、グラム陽性およびグラム陰性細菌の両方の少なくとも90%を該微生物との接触の20秒以内に死滅させる、
方法。 - 即時型微生物減少の方法であって、
複数の微生物により汚染された表面に局所製剤を適用することを含み、
前記局所製剤が、テルペンと、酢酸トコフェロールと、ポリアミノプロピルビグアナイドと、塩化ベンゼトニウムおよび塩化ベンザルコニウムからなる群から選択される少なくとも1つの第四級アンモニウム塩と、を含み、
前記製剤が、前記複数の微生物の少なくとも90%を該微生物との接触の20秒以内に死滅させ、
前記複数の微生物が次のうち2以上:グラム陽性細菌、グラム陰性細菌、真菌およびウイルス、を含む、
方法。 - 前記製剤が、清浄剤、スクラブ剤、ジェル、ローション、クリーム、起泡性石鹸および固形石鹸からなる群から選択される形態に作製される、先行する請求項の何れか1項に記載の方法。
- 前記製剤が、ボディーウォッシュ、シャンプー、コンディショナーおよび化粧品基剤からなる群から選択されるさらなる製剤への組み込みに適切である、先行する請求項の何れか1項に記載の方法。
- 前記微生物減少がブタ皮膚試験を用いて測定される、先行する請求項の何れか1項に記載の方法。
- グラム陽性およびグラム陰性細菌の即時型および持続型両方の減少のための二重作用抗微生物製剤であって、
前記製剤の約0.10重量%から約0.40重量%の範囲の量の第四級アンモニウム塩であって、塩化ベンゼトニウム、塩化ベンザルコニウムまたはそれらの組み合わせを含む第四級アンモニウム塩と;
前記製剤の約0.25重量%から約0.60重量%の範囲の量のテルペンまたはその誘導体と;
前記製剤の約0.05重量%から約0.5重量%の範囲の量の酢酸トコフェロールと;
前記製剤の約0.05重量%から約0.20重量%の範囲の量のポリアミノプロピルビグアナイドと、を含み、
グラム陽性およびグラム陰性細菌の両方の少なくとも99%を該微生物との接触の20秒以内に死滅させ、
前記製剤が、前記製剤適用の少なくとも4時間後に、グラム陽性およびグラム陰性細菌の両方の少なくとも90%を死滅させるように作製される、
製剤。 - 広域スペクトル微生物の即時型および持続型両方の減少のための二重作用抗微生物製剤であって、
前記製剤の約0.10重量%から約0.40重量%の範囲の量の第四級アンモニウム塩であって、塩化ベンゼトニウム、塩化ベンザルコニウムまたはそれらの組み合わせを含む第四級アンモニウム塩と;
前記製剤の約0.25重量%から約0.60重量%の範囲の量のテルペンまたはその誘導体と;
前記製剤の約0.05重量%から約0.5重量%の範囲の量の酢酸トコフェロール
と;
該製剤の約0.05重量%から約0.20重量%の範囲の量のポリアミノプロピルビグアナイドと、を含み、
複数の微生物の少なくとも99%を前記微生物との接触の20秒以内に死滅させ、
前記製剤が、前記製剤適用の少なくとも4時間後に、前記複数の微生物の少なくとも90%を死滅させるように作製され、
前記複数の微生物が、次のうち2以上:グラム陽性細菌、グラム陰性細菌、真菌およびウイルス、を含む、
製剤。 - 前記製剤が、グラム陽性およびグラム陰性細菌および/または複数の微生物に感染した表面への適用に適切である、請求項59または60に記載の製剤。
- 前記感染表面がヒト皮膚または無機表面である、請求項61に記載の製剤。
- 前記テルペンが、前記局所製剤中に該製剤の約0.25重量%から約0.60重量%の範囲の量で存在する、請求項59または60に記載の製剤。
- 前記酢酸トコフェロールが、前記局所製剤中に該製剤の約0.05重量%から約0.5重量%の範囲の量で存在する、請求項59または60に記載の製剤。
- 前記ポリアミノプロピルビグアナイドが、前記製剤の約0.05重量%から約0.20重量%の範囲の量で存在する、請求項59または60に記載の製剤。
- 前記第四級アンモニウム塩が、塩化ベンゼトニウムを含む、請求項59または60に記載の製剤。
- 前記局所製剤が、該製剤の約8重量%から約20重量%の範囲の量のアルコールをさらに含む、請求項59または60に記載の製剤。
- 前記局所製剤が、該製剤の約0.10重量%から約0.40重量%の範囲の量のグルコン酸クロルヘキシジンをさらに含む、請求項59または60に記載の製剤。
- 前記局所製剤が、該製剤の約0.05重量%から約0.20重量%の範囲の量のヒドロキシエチルエチルセルロースをさらに含む、請求項59または60に記載の製剤。
- 前記局所製剤が、該製剤の約0.05重量%から約0.60重量%の範囲の量の1以上の亜鉛塩をさらに含む、請求項59または60に記載の製剤。
- 前記1以上の亜鉛塩が乳酸亜鉛を含む、請求項70に記載の製剤。
- 前記1以上の亜鉛塩がグルコン酸亜鉛を含む、請求項70に記載の製剤。
- 前記局所製剤が、該製剤の約0.25重量%から約0.60重量%の範囲の量のパンテノールをさらに含む、請求項59または60に記載の製剤。
- 前記テルペンまたはその誘導体がセスキテルペンを含む、請求項59から73の何れか1項に記載の製剤。
- 前記テルペンまたはその誘導体がファルネソールを含む、請求項59から73の何れか1項に記載の製剤。
- 前記局所製剤が、1以上のさらなる皮膚軟化薬化合物をさらに含む、請求項59から75の何れか1項に記載の製剤。
- 前記局所製剤が、ビタミンA、B、KおよびCのうち1以上をさらに含む、請求項59から76の何れか1項に記載の製剤。
- 前記局所製剤が精油をさらに含む、請求項59から77の何れか1項に記載の製剤。
- 前記精油がユーカリ油を含む、請求項78に記載の製剤。
- 前記ユーカリ油が、前記製剤の約0.05重量%から約0.5重量%の範囲の量で存在する、請求項79に記載の製剤。
- 前記二重作用抗微生物効果が、グラム陽性およびグラム陰性細菌および/または複数の微生物に感染した表面上に約0.1から0.8mLの前記製剤を施与することによって達成される、請求項59から80の何れか1項に記載の製剤。
- 前記即時型および持続型抗微生物効果が前記製剤の単回投与を用いて達成される、請求項59から80の何れか1項に記載の製剤。
- 微生物減少のための抗微生物製剤であって、
前記製剤の約8重量%から約20重量%の範囲の量のアルコールと;
前記製剤の約0.10重量%から約0.40重量%の範囲の量のグルコン酸クロルヘキシジンと;
前記製剤の約0.10重量%から約0.40重量%の範囲の量の第四級アンモニウム塩であって、塩化ベンゼトニウム、塩化ベンザルコニウムまたはそれらの組み合わせを含む第四級アンモニウム塩と;
前記製剤の約0.05重量%から約0.20重量%の範囲の量のヒドロキシエチルエチルセルロースと;
前記製剤の約0.05重量%から約0.60重量%の範囲の量の亜鉛塩と;
前記製剤の約0.25重量%から約0.60重量%の範囲の量のテルペンまたはその誘導体と;
前記製剤の約0.05重量%から約0.20重量%の範囲の量のポリマー性ビグアナイドであって、ポリアミノプロピルビグアナイドを含むポリマー性ビグアナイドと;
前記製剤の約0.25重量%から約0.60重量%の範囲の量のパンテノールと;
前記製剤の約0.05重量%から約0.5重量%の範囲の量の酢酸トコフェロールと、を含み、
前記製剤が、前記微生物の少なくとも99%を該微生物との接触の20秒以内に死滅させ、
前記製剤の微生物死滅効果が、少なくとも4時間にわたり90%を超えて持続し、
前記微生物が、ウイルス、グラム陽性細菌、グラム陰性細菌、薬物耐性細菌、カビ、酵母、真菌およびそれらの組み合わせのうち1以上を含む、
抗微生物製剤。 - 前記亜鉛塩が乳酸亜鉛である、請求項83に記載の製剤。
- 前記亜鉛塩がグルコン酸亜鉛である、請求項83に記載の製剤。
- 前記テルペンまたはその誘導体がセスキテルペンを含む、請求項83から85の何れか1項に記載の製剤。
- 前記テルペンまたはその誘導体がファルネソールを含む、請求項83から85の何れか1項に記載の製剤。
- 前記第四級アンモニウム塩が塩化ベンゼトニウムを含む、請求項83から85の何れか1項に記載の製剤。
- 1以上のさらなる皮膚軟化薬化合物をさらに含む、請求項83から88の何れか1項に記載の製剤。
- ビタミンA、B、KおよびCのうち1以上をさらに含む、請求項83から89の何れか1項に記載の製剤。
- 精油をさらに含む、請求項83から90の何れか1項に記載の製剤。
- 前記精油がユーカリ油を含む、請求項91に記載の製剤。
- 前記ユーカリ油が、前記製剤の約0.05重量%から約0.5重量%の範囲の量で存在する、請求項92に記載の製剤。
- 前記アルコールが、前記製剤の約8重量%から約15重量%の範囲の量で存在する、請求項83から93の何れか1項に記載の製剤。
- 前記グルコン酸クロルヘキシジンが、前記製剤の約0.10重量%から約0.30重量%の範囲の量で存在する、請求項83から94の何れか1項に記載の製剤。
- 前記第四級アンモニウム塩が、前記製剤の約0.10重量%から約0.30重量%の範囲の量で存在する、請求項83から95の何れか1項に記載の製剤。
- 前記ヒドロキシエチルエチルセルロースが、前記製剤の約0.05重量%から約0.15重量%の範囲の量で存在する、請求項83から96の何れか1項に記載の製剤。
- 前記亜鉛塩が、前記製剤の約0.05重量%から約0.25重量%の範囲の量で存在する、請求項83から97の何れか1項に記載の製剤。
- 前記テルペノイドまたはその誘導体が、前記製剤の約0.30重量%から約0.60重量%の範囲の量で存在する、請求項83から98の何れか1項に記載の製剤。
- 前記パンテノールが、前記製剤の約0.30重量%から約0.60重量%の範囲の量で存在する、請求項83から99の何れか1項に記載の製剤。
- 前記製剤が局所使用に適している、請求項83から100の何れか1項に記載の製剤。
- 前記製剤が表面の処理に適している、請求項83から101の何れか1項に記載の製剤。
- 短時間および持続型死滅効果が、約0.2から0.8mLの範囲の体積での前記製剤の単回投与を使用して達成される、請求項83から102の何れか1項に記載の製剤。
- 表面上での短時間および持続型の広域スペクトルの微生物減少のための方法であって、
a)製剤の約8重量%から約20重量%の範囲の量のアルコールまたは前記製剤の約0.10重量%から約0.40重量%の範囲の量のグルコン酸クロルヘキシジンと;
b)前記製剤の約0.10重量%から約0.40重量%の範囲の量の第四級アンモニウム塩であって、塩化ベンゼトニウム、塩化ベンザルコニウムまたはそれらの組み合わせを含む第四級アンモニウム塩と;
c)前記製剤の約0.05重量%から約0.20重量%の範囲の量のヒドロキシエチルエチルセルロースと;
d)前記製剤の約0.05重量%から約0.60重量%の範囲の量の亜鉛塩と;
e)前記製剤の約0.25重量%から約0.60重量%の範囲の量のテルペノイドまたはその誘導体と;
f)前記製剤の約0.05重量%から約0.20重量%の範囲の量のポリマー性ビグアナイドであって、ポリアミノプロピルビグアナイドを含むポリマー性ビグアナイドと;
g)前記製剤の約0.25重量%から約0.60重量%の範囲の量のパンテノールと;
h)前記製剤の約0.05重量%から約0.5重量%の範囲の量の酢酸トコフェロールと、
を含む抗微生物ローションと前記表面を接触させることを含み;
前記微生物が、ウイルス、グラム陽性細菌、グラム陰性細菌、薬物耐性細菌、カビ、酵母、真菌のうち1以上を含み、
前記接触の結果、前記微生物の少なくとも99%が20秒以内に死滅し、
前記接触の結果、少なくとも4時間にわたり前記微生物の90%超の持続型死滅効果が得られる、
方法。 - 前記表面が対象の皮膚表面である、請求項104に記載の方法。
- 前記対象がヒトである、請求項105に記載の方法。
- 前記接触が、約0.1から0.8mLの前記ローションを前記表面上に施与することを含む、請求項104から106の何れか1項に記載の方法。
- 前記亜鉛塩が乳酸亜鉛である、請求項104から107の何れか1項に記載の方法。
- 前記亜鉛塩がグルコン酸亜鉛である、請求項104から108の何れか1項に記載の方法。
- 前記テルペンまたはその誘導体がセスキテルペンを含む、請求項104から109の何れか1項に記載の方法。
- 前記テルペンまたはその誘導体がファルネソールを含む、請求項110に記載の方法。
- 前記第四級アンモニウム塩が塩化ベンゼトニウムを含む、請求項104から111の何れか1項に記載の方法。
- 前記製剤が、1以上のさらなる皮膚軟化薬化合物をさらに含む、請求項104から112の何れか1項に記載の方法。
- 前記製剤が、ビタミンA、B、KおよびCのうち1以上をさらに含む、請求項104から113の何れか1項に記載の方法。
- 前記製剤が精油をさらに含む、請求項104から114の何れか1項に記載の方法。
- 前記精油がユーカリ油を含む、請求項115に記載の方法。
- 前記ユーカリ油が、前記製剤の約0.05重量%から約0.5重量%の範囲の量で存在する、請求項116に記載の方法。
- 表面上での短時間および持続型の微生物量減少のための方法であって、
a)製剤の約8重量%から約20重量%の範囲の量のアルコールまたは前記製剤の約0.10重量%から約0.40重量%の範囲の量のグルコン酸クロルヘキシジンと;
b)前記製剤の約0.10重量%から約0.40重量%の範囲の量の第四級アンモニウム塩であって、塩化ベンゼトニウム、塩化ベンザルコニウムまたはそれらの組み合わせを含む第四級アンモニウム塩と;
c)前記製剤の約0.05重量%から約0.20重量%の範囲の量のヒドロキシエチルエチルセルロースと;
d)前記製剤の約0.05重量%から約0.60重量%の範囲の量の亜鉛塩と;
e)前記製剤の約0.25重量%から約0.60重量%の範囲の量のテルペノイドまたはその誘導体と;
e)前記製剤の約0.25重量%から約0.60重量%の範囲の量のパンテノールと、
を含む抗微生物製剤と前記表面を接触させることを含み;
前記接触の結果、20秒以内に前記微生物の少なくとも99%が死滅し、
前記接触の結果、少なくとも4時間にわたり前記微生物の90%超の持続型死滅効果が生じ、
前記微生物が、ウイルス、グラム陽性細菌、グラム陰性細菌、薬物耐性細菌、カビ、酵母、真菌およびそれらの組み合わせのうち1以上を含む、
方法。 - 前記表面が対象の皮膚表面である、請求項118に記載の方法。
- 微生物減少のための抗微生物製剤であって、前記製剤の約8重量%から約20重量%の範囲の量のアルコールと;
前記製剤の約0.10重量%から約0.40重量%の範囲の量のグルコン酸クロルヘキシジンと;
前記製剤の約0.10重量%から約0.40重量%の範囲の量の第四級アンモニウム塩であって、塩化ベンゼトニウム、塩化ベンザルコニウムまたはそれらの組み合わせを含む第四級アンモニウム塩と;
前記製剤の約0.05重量%から約0.20重量%の範囲の量のヒドロキシエチルエチルセルロースと;
前記製剤の約0.05重量%から約0.60重量%の範囲の量の亜鉛塩と;
前記製剤の約0.25重量%から約0.60重量%の範囲の量のテルペノイドまたはその誘導体と;
前記製剤の約0.25重量%から約0.60重量%の範囲の量のパンテノールと、を含み、
前記製剤が、前記微生物の少なくとも99%を該微生物との接触の20秒以内に死滅させ、
前記製剤の微生物死滅効果が、少なくとも4時間にわたり90%を超えて持続し、
前記微生物が、ウイルス、グラム陽性細菌、グラム陰性細菌、薬物耐性細菌、カビ、酵母、真菌およびそれらの組み合わせのうち1以上を含む、
抗微生物製剤。 - 表面上での短時間および持続型の感染性微生物減少のための方法であって、
a)製剤の約8重量%から約20重量%の範囲の量のアルコールまたは前記製剤の約0.10重量%から約0.40重量%の範囲の量のグルコン酸クロルヘキシジンと;
b)前記製剤の約0.10重量%から約0.40重量%の範囲の量の第四級アンモニウム塩であって、塩化ベンゼトニウム、塩化ベンザルコニウムまたはそれらの組み合わせを含む第四級アンモニウム塩と;
c)前記製剤の約0.05重量%から約0.20重量%の範囲の量のヒドロキシエチルエチルセルロースと;
d)前記製剤の約0.05重量%から約0.60重量%の範囲の量の亜鉛塩と;
e)前記製剤の約0.25重量%から約0.60重量%の範囲の量のテルペノイドまたはその誘導体と;
f)前記製剤の約0.05重量%から約0.20重量%の範囲の量のポリマー性ビグアナイドであって、ポリアミノプロピルビグアナイドを含むポリマー性ビグアナイドと;
g)前記製剤の約0.25重量%から約0.60重量%の範囲の量のパンテノールと、
を含む抗微生物ローションと前記表面を接触させることを含み;
前記接触の結果、20秒以内に前記微生物の少なくとも99%が死滅し、
前記接触の結果、少なくとも4時間にわたり前記微生物の90%超の持続型死滅効果が生じ、
前記微生物が、ウイルス、グラム陽性細菌、グラム陰性細菌、薬物耐性細菌、カビ、酵母、真菌およびそれらの組み合わせのうち1以上を含む、
方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261674779P | 2012-07-23 | 2012-07-23 | |
US61/674,779 | 2012-07-23 | ||
PCT/US2013/051398 WO2014018417A1 (en) | 2012-07-23 | 2013-07-19 | Topical sanitizing formulations and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015524804A true JP2015524804A (ja) | 2015-08-27 |
JP2015524804A5 JP2015524804A5 (ja) | 2016-10-27 |
JP6549483B2 JP6549483B2 (ja) | 2019-07-24 |
Family
ID=49997748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015524357A Active JP6549483B2 (ja) | 2012-07-23 | 2013-07-19 | 局所消毒用製剤およびその使用 |
Country Status (12)
Country | Link |
---|---|
US (5) | US9717669B2 (ja) |
EP (1) | EP2874616A4 (ja) |
JP (1) | JP6549483B2 (ja) |
KR (2) | KR102309187B1 (ja) |
AU (4) | AU2013293264B2 (ja) |
CA (2) | CA2918491C (ja) |
IL (2) | IL236829A0 (ja) |
IN (1) | IN2015DN01198A (ja) |
MX (2) | MX352985B (ja) |
SG (2) | SG11201500352QA (ja) |
WO (1) | WO2014018417A1 (ja) |
ZA (1) | ZA201500437B (ja) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201211701D0 (en) | 2012-07-02 | 2012-08-15 | Reckitt Benckiser Llc | Aqueous alcoholic microbicidal compositions comprising zinc ions |
GB201211688D0 (en) | 2012-07-02 | 2012-08-15 | Reckitt Benckiser Llc | Aqueous alcoholic microbicidal compositions comprising zinc ions |
GB201211702D0 (en) | 2012-07-02 | 2012-08-15 | Reckitt Benckiser Llc | Sprayable aqueous alcoholic microbicidal compostions comprising zinc ions |
GB201211691D0 (en) | 2012-07-05 | 2012-08-15 | Reckitt Benckiser Llc | Sprayable aqueous alcoholic microbicidal compositions comprising zinc ions |
WO2014083330A1 (en) * | 2012-11-30 | 2014-06-05 | Reckitt & Colman (Overseas) Limited | Microbicidal personal care compositions comprising metal ions |
GB2544216B (en) * | 2014-07-31 | 2021-09-22 | Kimberly Clark Co | Anti-adherent composition |
WO2016018475A1 (en) | 2014-07-31 | 2016-02-04 | Kimberly-Clark Worldwide, Inc. | Anti-adherent composition |
GB2547341B (en) | 2014-07-31 | 2022-08-17 | Kimberly Clark Co | Anti-adherent composition |
WO2016018476A1 (en) * | 2014-07-31 | 2016-02-04 | Kimberly-Clark Worldwide, Inc. | Anti-adherent alcohol-based composition |
WO2016093882A1 (en) * | 2014-12-08 | 2016-06-16 | Kinnos Inc. | Additive compositions for pigmented disinfection and methods thereof |
AU2015390078B2 (en) | 2015-04-01 | 2020-11-26 | Kimberly-Clark Worldwide, Inc. | Fibrous substrate for capture of Gram negative bacteria |
AU2016377340B2 (en) * | 2015-12-22 | 2019-10-31 | 3M Innovative Properties Company | Methods for spore removal |
BR112018016369A2 (pt) | 2016-02-12 | 2018-12-26 | Kinnos Inc | composições e métodos para uso na descontaminação de superfície |
GB2565511B (en) | 2016-05-26 | 2022-04-13 | Kimberly Clark Co | Anti-adherent compositions and methods of inhibiting the adherence of microbes to a surface |
CN114736749A (zh) | 2016-07-25 | 2022-07-12 | 金诺斯公司 | 用于表面净化的装置和相关组合物及方法 |
US11292994B2 (en) * | 2017-09-07 | 2022-04-05 | Ccmp Spe I, Llc | Alcohol-potentiated antimicrobial formulations containing a disinfectant mixture |
BR112020014234A2 (pt) | 2018-01-14 | 2020-12-08 | Collidion, Inc. | Composições, kits, métodos e usos para limpeza, desinfecção, esterilização e/ou tratamento |
WO2019215679A1 (en) | 2018-05-10 | 2019-11-14 | Protair-X Health Solutions, Inc. | Foam sanitizer composition |
WO2020014612A1 (en) | 2018-07-12 | 2020-01-16 | Kinnos Inc. | Devices, compositions, and methods for use in surface decontamination |
US20200078273A1 (en) * | 2018-09-07 | 2020-03-12 | Michael J. McKinnon-Dane | Method and apparatus for removal of contaminants from surfaces |
WO2021260662A1 (en) * | 2020-06-26 | 2021-12-30 | Farahmnad Farrokh | Non-alcoholic antiseptic gel consists of benzalkonium chloride |
US20220000733A1 (en) * | 2020-06-30 | 2022-01-06 | Mary Kay Inc. | Alcohol-based sanitizer formulation for topical application |
US11083231B1 (en) | 2020-12-08 | 2021-08-10 | Randall J Lewis | Sanitizing face mask |
CN113648303B (zh) * | 2021-08-20 | 2022-12-20 | 中山大学 | 咖啡醇或其衍生物在制备抗白色念珠菌药物或抗白色念珠菌日用品中的应用 |
WO2023126229A1 (en) | 2021-12-27 | 2023-07-06 | Unilever Ip Holdings B.V. | Liquid composition having enhanced antimicrobial activity |
CN114652741B (zh) * | 2022-01-19 | 2023-08-25 | 昆明野水生物科技有限公司 | 一种用于抑制hpv的组合物、制剂及其应用 |
KR102607031B1 (ko) * | 2023-04-26 | 2023-11-29 | (주)에이치피앤씨 | 벤잘코늄 염화물의 원단 흡착률이 개선된 소독제용 조성물 및 소독티슈 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006096239A1 (en) * | 2005-03-08 | 2006-09-14 | Ecolab Inc. | Hydroalcoholic antimicrobial composition with skin health benefits |
JP2008531472A (ja) * | 2005-01-07 | 2008-08-14 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 亜鉛塩含有非刺激性組成物 |
JP2011511052A (ja) * | 2008-02-07 | 2011-04-07 | レキット ベンキッサー インコーポレイテッド | 局所抗菌組成物 |
JP2012504594A (ja) * | 2008-10-02 | 2012-02-23 | ヒェーミシェス・インスティトゥート・シェーファー・アクチェンゲゼルシャフト | 粘液様の組成物およびその使用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69533724T2 (de) | 1994-03-28 | 2005-10-27 | The Trustees Of Columbia University In The City Of New York | Zusammensetzung zum inaktivieren von reizstoffen in flüssigkeiten |
US5985918A (en) | 1996-12-04 | 1999-11-16 | The Trustees Of Columbia University In The City Of New York | Zinc-based antiirritant creams |
US6183766B1 (en) | 1999-02-12 | 2001-02-06 | The Procter & Gamble Company | Skin sanitizing compositions |
WO2001021138A1 (en) | 1999-09-22 | 2001-03-29 | First Scientific, Inc. | Antimicrobial topical composition and methods |
DE10021056A1 (de) | 2000-04-28 | 2001-10-31 | Henkel Kgaa | Antitranspirant-Zusammensetzung |
US7745425B2 (en) | 2002-02-07 | 2010-06-29 | The Trustees Of Columbia University In The City Of New York | Non-irritating compositions containing zinc salts |
US7435429B2 (en) | 2002-02-07 | 2008-10-14 | Trustees Of Columbia University In The City Of New York | Zinc salt compositions for the prevention of dermal and mucosal irritation |
CA2475224C (en) | 2002-02-07 | 2011-11-01 | The Trustees Of Columbia University In The City Of New York | Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides |
US7879365B2 (en) | 2002-02-07 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Zinc salt compositions for the prevention of dermal and mucosal irritation |
KR20050107814A (ko) * | 2003-03-19 | 2005-11-15 | 가부시키가이샤 가네보케쇼힝 | 화장료 |
JP2007534620A (ja) | 2003-07-17 | 2007-11-29 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 第4級アンモニウム化合物と精油および/またはその構成要素の相乗的組合せを含む抗菌組成物 |
US20050095215A1 (en) | 2003-11-03 | 2005-05-05 | Popp Karl F. | Antimicrobial shampoo compositions |
US7759327B2 (en) | 2006-01-06 | 2010-07-20 | The Trustees Of Columbia University In The City Of New York | Compositions containing zinc salts for coating medical articles |
MX2009013317A (es) | 2007-06-07 | 2010-01-29 | Univ Columbia | Limpiador desinfectante de efecto prolongado. |
AU2008316312B2 (en) | 2007-10-23 | 2015-03-26 | Wild Child Wa Pty Ltd | Anti-microbial composition |
AU2008347253B2 (en) * | 2007-12-31 | 2012-04-19 | 3M Innovative Properties Company | Antimicrobial compositions |
KR101515176B1 (ko) | 2008-07-10 | 2015-04-24 | 시므라이즈 아게 | 벤질알코올 유도체 및 추가적인 항균활성 화합물을 포함하는 조성물 |
US20110257125A1 (en) | 2008-10-02 | 2011-10-20 | Rolf Schaefer | Mucomimetic compositions and uses therefore |
US9149567B2 (en) * | 2009-03-11 | 2015-10-06 | Ansell Limited | Powder-free antimicrobial coated glove |
US8388991B2 (en) | 2009-05-01 | 2013-03-05 | Chattem, Inc. | Moisturizing antimicrobial composition |
WO2011099665A1 (ko) | 2010-02-12 | 2011-08-18 | 주식회사 케이씨아이 | 천연 원료 추출물을 포함하는 항균 조성물, 복합 천연 방부제 및 이들의 제조방법 |
-
2013
- 2013-07-19 SG SG11201500352QA patent/SG11201500352QA/en unknown
- 2013-07-19 KR KR1020207012473A patent/KR102309187B1/ko active IP Right Grant
- 2013-07-19 US US14/416,010 patent/US9717669B2/en active Active
- 2013-07-19 MX MX2015000995A patent/MX352985B/es active IP Right Grant
- 2013-07-19 JP JP2015524357A patent/JP6549483B2/ja active Active
- 2013-07-19 EP EP13822506.5A patent/EP2874616A4/en active Pending
- 2013-07-19 MX MX2017016348A patent/MX363004B/es unknown
- 2013-07-19 KR KR1020157003213A patent/KR102108109B1/ko active Application Filing
- 2013-07-19 CA CA2918491A patent/CA2918491C/en active Active
- 2013-07-19 WO PCT/US2013/051398 patent/WO2014018417A1/en active Application Filing
- 2013-07-19 CA CA3126679A patent/CA3126679A1/en active Pending
- 2013-07-19 SG SG10201610654XA patent/SG10201610654XA/en unknown
- 2013-07-19 AU AU2013293264A patent/AU2013293264B2/en active Active
-
2015
- 2015-01-21 ZA ZA2015/00437A patent/ZA201500437B/en unknown
- 2015-01-21 IL IL236829A patent/IL236829A0/en unknown
- 2015-02-13 IN IN1198DEN2015 patent/IN2015DN01198A/en unknown
-
2017
- 2017-07-31 US US15/664,542 patent/US10010496B2/en active Active
- 2017-11-23 AU AU2017265091A patent/AU2017265091B2/en active Active
-
2018
- 2018-06-18 US US16/010,781 patent/US10524997B2/en active Active
-
2019
- 2019-05-14 AU AU2019203378A patent/AU2019203378A1/en not_active Abandoned
-
2020
- 2020-01-06 US US16/735,547 patent/US11110048B2/en active Active
-
2021
- 2021-06-18 AU AU2021204094A patent/AU2021204094B2/en active Active
- 2021-09-02 US US17/465,546 patent/US20220125699A1/en active Pending
-
2022
- 2022-01-11 IL IL289759A patent/IL289759A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008531472A (ja) * | 2005-01-07 | 2008-08-14 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 亜鉛塩含有非刺激性組成物 |
WO2006096239A1 (en) * | 2005-03-08 | 2006-09-14 | Ecolab Inc. | Hydroalcoholic antimicrobial composition with skin health benefits |
JP2011511052A (ja) * | 2008-02-07 | 2011-04-07 | レキット ベンキッサー インコーポレイテッド | 局所抗菌組成物 |
JP2012504594A (ja) * | 2008-10-02 | 2012-02-23 | ヒェーミシェス・インスティトゥート・シェーファー・アクチェンゲゼルシャフト | 粘液様の組成物およびその使用 |
Non-Patent Citations (2)
Title |
---|
フレグランスジャーナル, 2006, VOL.34(4), P.28-33, JPN6017014277 * |
フレグランスジャーナル, 2010, VOL.38(9), P.87-89, JPN6017014275 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021204094B2 (en) | Topical sanitizing formulations and uses thereof | |
US20140011766A1 (en) | Antimicrobial compositions and methods | |
WO2006097758A2 (en) | Antimicrobial composition | |
US9895407B2 (en) | Disinfecting formulations and uses thereof | |
Kampf et al. | Efficacy of surgical hand scrub products based on chlorhexidine is largely overestimated without neutralizing agents in the sampling fluid | |
Gaonkar et al. | In vivo efficacy of an alcohol-based surgical hand disinfectant containing a synergistic combination of ethylhexylglycerin and preservatives | |
WO2021259211A1 (en) | Antiseptic compositions | |
Peters | ANMF Evidence Brief Covid-19: Hand Sanitiser Ingredients | |
WO2021259215A1 (en) | Antiseptic compositions | |
Yi et al. | Analysis of Antimicrobial Activity Using Hand Sanitizers | |
Shintre et al. | Evaluation of an alcohol-based surgical hand disinfectant containing a synergistic combination of farnesol and benzethonium chloride for immediate and persistent activity against resident hand flora of volunteers and with a novel in vitro pig skin model | |
JP2023529385A (ja) | 組成物 | |
CN106580939A (zh) | 葡萄糖酸洗必泰消毒液 | |
WO2015038606A1 (en) | Antimicrobial compositions and method | |
MXPA06005233A (es) | Composicion desinfectante y metodos para hacerla y usarla |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160715 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160715 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170425 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170724 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170919 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170920 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180220 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180521 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180717 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20181106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190228 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190422 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190528 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190627 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6549483 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |